Aspira Women's Health Inc. · OTC:AWHL
Aspira Women's Health — Investor Presentation (June 2022)
19 slides from Aspira Women's Health's investor presentation, Jun 6, 2022

Slide 1: Transforming the State of Women's Gynecological Health… Starting with Ovarian Cancer
Transforming the State of Women’s Gynecological Health… Starting with Ovarian Cancer Corporate Presentation | June 2022 Nicole Sandford, President and CEO Bob Beechey, Chief Financial Officer

Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. These forward-looking statements include, am

Slide 3: Investment Highlights
Investment Highlights Commercial Revenue-generating test for multi-modal ovarian cancer risk assessment Test FDA-cleared Proprietary technology included in clinical treatment guidelines Technologies Focused Compelling pipeline of gynecological diagnostic tools Pipeline Intellectual Strong IP and tec

Slide 4: Recent Developments
Recent Developments Aspira will collaborate with BioReference Laboratories, Inc., an OPKO Health company and the largest full-service specialty laboratory in the United States, to offer OVA1Plus, which includes Aspira’s FDA-cleared Ova1 and Overa ovarian cancer risk assessments. • With a leading pos

Slide 5: Starting with Ovarian Cancer …
Starting with Ovarian Cancer … Most Ovarian Cancer Detected at Late Stage – When It’s Most Deadly Presentation Stage I Stage II Stage III Stage IV Stage Local Pelvic Regional nodes Distant spread Incidence 15% 21% 59% 6% Five Year 92% 75% 29% 24% Survival Rate1 Ovarian Cancer Diagnosed in the Late S

Slide 6: Current Standard of Care for Assessing Cancer Treatment
Current Standard of Care for Assessing Cancer Treatment Blood Tumor Tissue Clinical Assessment Marker Analysis Physical exam and ultrasound CA 125 (off-label) Pre-operative biopsy not ROMA™ (alternative) recommended Limitations: Subjective results and Limitations: Low sensitivity and Limitations: Hi

Slide 7: A Better Blood Risk Assessment
A Better Blood Risk Assessment OVA products demonstrate better performance in early-stage risk detection 5% OVA risk assessment products 31% 31% substantially improve the effectiveness of clinical 95% assessment in stratifying 69% the risk of Stage 1 and Stage 2 malignancy for women with pelvic mass

Slide 8: Significant Market Opportunity
Significant Market Opportunity OVA products address the unmet need and represent a significant growth opportunity for Aspira. OVA1Plus Pelvic Mass – Potential Revenue Women Planned For Surgery $100M-140M TAM=300-400K OVAWatch Pelvic Mass (one time and Potential Revenue serial mass monitoring) $200-3

Slide 9: Commercial Strategy
Commercial Strategy The expansion and commercialization of our OVA products is a top priority for 2022 Commercial Strategy Focus Sales Force Optimization Targeting gynecologic specialists, Expanded Adoption and Coverage 26 full-time women’s health access via specialized sales groups and agreements p

Slide 10: OVA Adoption Since Introduction of Second-Generation Test
Sales Force Optimization Adoption and OVA Adoption Since Introduction of Second-Generation Test Coverage Product Expansion Platforms and Partnerships OVA volumes have increased over time even during the Covid pandemic Professional Society Support 5000 4819 4750 4553 4500 4281 OVA Test Volume 4000 38

Slide 11: OVA Adoption by Physicians Continues to Improve
Sales Force Optimization Adoption and OVA Adoption by Physicians Continues to Improve Coverage Product Expansion Total Ordering Physicians Platforms and Partnerships 3500 Physician Testimonials 3000 OVA1plus™ has made a big difference in my practice because it has added more 2500 certainty to decisi

Slide 12: Market Access
Sales Force Optimization Adoption and Market Access Coverage Product Expansion Our goal is to make OVA products available to all women Platforms and Partnerships 168 Million Commercial lives covered 48 Million Medicaid lives covered Commercial coverage also includes Medicare Advantage plans ■ Covere

Slide 13: OVAWatch is our third generation OVA product
Sales Force Optimization Adoption and Coverage Product Expansion Platforms and Partnerships OVAWatch is our third generation OVA product. It is a non-invasive Lab Developed Test (LDT) to be used in conjunction with clinical assessment to determine the risk of ovarian cancer for patients with an adne

Slide 14: Launch Plan
Sales Force Optimization Adoption and Coverage Product Expansion Platforms and Launch Plan Partnerships 05 Initial Commercial Launch 2H 2022 Targeted for second half 2022; revenue in 2023 04 Pricing/Reimbursement Cross-walk from existing reimbursement In process arrangements for OVA1Plus 03 Clinical

Slide 15: Endometriosis is an Unmet Need – and Market Opportunity
Sales Force Optimization Adoption and Endometriosis is an Unmet Need – and Market Opportunity Coverage Product Expansion Platforms and Partnerships Health Cost 6-7million Burden women affected in the U.S. by Endometriosis For women diagnosed with • EndoCheck™ is our in-development Endometriosis in t

Slide 16: Aspira Synergy: Phases of the Client Relationship Lifecycle
Sales Force Optimization Adoption and Aspira Synergy: Phases of the Client Relationship Lifecycle Coverage Product Expansion Platforms and Partnerships Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 Agreement Implementation Launch Adoption/Scale Optimization Super Group A Sales and Adoption: Revenue Drive

Slide 17: Financial Performance Snapshot
Financial Performance Snapshot Q1 vs. Last Year Q1 vs. Last quarter Cash Position OVA Product Volume OVA Product Volume Cash as of March 31, 2022 INCREASED 28% INCREASED 1% $27.1M 4,819 units in Q1FY22 vs. 4,819 units in Q1FY22 vs. 3,775 units in Q1FY21 4,750 units in Q4FY21 Cash Used in Operations

Slide 18: In Conclusion ... 2022 is about Focused Execution
In Conclusion ... Our strategy is sound, the path forward is clear. 2022 is about Focused Execution Accelerated Adoption and Volume Initial Launch Development Operational Excellence 18

Slide 19: Contact Information
Contact Information Ashley R. Robinson LifeSci Advisors, LLC [email protected]
Source: Internet Archive copy of ir.aspirawh.com
More decks from Aspira Women's Health Inc.
Investor Presentation (December 2025)35 slides · Dec 31, 2025
Investor Presentation (January 2025)26 slides · Jan 13, 2025
Technical Presentation (October 2024)47 slides · Oct 29, 2024
Investor Day (October 2024)42 slides · Oct 29, 2024
Investor Presentation (September 2024)30 slides · Sep 13, 2024
Fact Sheet (June 2024)2 slides · June 2024